MarketBeat Instant News Alerts 2 hours agoUltragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst UpgradeMarketBeatUltragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase Following Analyst UpgradeNASDAQ:RARERead Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst Upgrade2 hours agoUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00MarketBeatCitigroup boosted their price target on Ultragenyx Pharmaceutical from $31.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday.NASDAQ:RARERead Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.002 hours agoCognizant Technology Solutions' (CTSH) Hold Rating Reaffirmed at TD CowenMarketBeatTD Cowen reissued a "hold" rating and set a $54.00 price target on shares of Cognizant Technology Solutions in a research report on Friday.NASDAQ:CTSHRead Cognizant Technology Solutions' (CTSH) Hold Rating Reaffirmed at TD Cowen2 hours agoMorgan Stanley Cuts Duke Energy (NYSE:DUK) Price Target to $127.00MarketBeatMorgan Stanley lowered their target price on shares of Duke Energy from $133.00 to $127.00 and set an "equal weight" rating on the stock in a report on Friday.NYSE:DUKRead Morgan Stanley Cuts Duke Energy (NYSE:DUK) Price Target to $127.002 hours agoMorgan Stanley Issues Pessimistic Forecast for DTE Energy (NYSE:DTE) Stock PriceMarketBeatMorgan Stanley cut their price target on DTE Energy from $148.00 to $141.00 and set an "overweight" rating for the company in a research note on Friday.NYSE:DTERead Morgan Stanley Issues Pessimistic Forecast for DTE Energy (NYSE:DTE) Stock Price2 hours agoMorgan Stanley Lowers Dominion Energy (NYSE:D) Price Target to $66.00MarketBeatMorgan Stanley reduced their price objective on shares of Dominion Energy from $68.00 to $66.00 and set an "equal weight" rating on the stock in a research report on Friday.NYSE:DRead Morgan Stanley Lowers Dominion Energy (NYSE:D) Price Target to $66.00 Trending News1Rivian Automotive (NASDAQ:RIVN) Insider Sells $244,350.00 in Stock2Nykredit A S Purchases Shares of 1,480,345 Netflix, Inc. $NFLX3Fannie Mae (OTCMKTS:FNMA) Shares Down 7.4% - Here's Why4Nicola Loporcaro Sells 1,457,102 Shares of GMR Solutions (NYSE:GMRS) Stock5Advanced Micro Devices (NASDAQ:AMD) CEO Lisa Su Sells 70,000 Shares of Stock6Reddit (NYSE:RDDT) COO Jennifer Wong Sells 60,000 Shares of Stock7QuantumScape Ramps Pilot Line as Solid-State Battery Markets Expand8Citigroup Issues Pessimistic Forecast for NIKE (NYSE:NKE) Stock Price All MarketBeat Instant News Alerts Latest News Trending News Sort By Last 24 Hours Last 3 Days Last 5 Days Last 7 Days Last 14 Days Last 30 Days Last 90 Days All Time Time Frame All Alerts Analyst Congressional Trades Consensus Corporate Buyback Corporate Event Transcript Dividend Earnings Earnings Preview Earnings Transcript Highlights Estimates Guidance Insider Trade Lockup Expiration MarketBeat List Articles Options Price SEC Filing Stock List Stock Split Alert Type Keywords 2 hours agoBowman Consulting Group Ltd. (NASDAQ:BWMN) Receives Consensus Rating of "Reduce" from BrokeragesMarketBeatNASDAQ:BWMNRead Bowman Consulting Group Ltd. (NASDAQ:BWMN) Receives Consensus Rating of "Reduce" from Brokerages2 hours agoAxoGen, Inc. (NASDAQ:AXGN) Receives Consensus Rating of "Moderate Buy" from BrokeragesMarketBeatNASDAQ:AXGNRead AxoGen, Inc. (NASDAQ:AXGN) Receives Consensus Rating of "Moderate Buy" from Brokerages2 hours agoBank of Hawaii Corporation (NYSE:BOH) Given Consensus Recommendation of "Hold" by BrokeragesMarketBeatNYSE:BOHRead Bank of Hawaii Corporation (NYSE:BOH) Given Consensus Recommendation of "Hold" by Brokerages2 hours agoCNO Financial Group, Inc. (NYSE:CNO) Given Average Rating of "Hold" by AnalystsMarketBeatNYSE:CNORead CNO Financial Group, Inc. (NYSE:CNO) Given Average Rating of "Hold" by Analysts2 hours agoSpruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarketBeatNASDAQ:SPRBRead Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Moderate Buy" from Brokerages2 hours agoMidCap Financial Investment Corporation (NASDAQ:MFIC) Receives Consensus Recommendation of "Hold" from AnalystsMarketBeatNASDAQ:MFICRead MidCap Financial Investment Corporation (NASDAQ:MFIC) Receives Consensus Recommendation of "Hold" from Analysts2 hours agoModine Manufacturing Company (NYSE:MOD) Given Consensus Rating of "Moderate Buy" by AnalystsMarketBeatNYSE:MODRead Modine Manufacturing Company (NYSE:MOD) Given Consensus Rating of "Moderate Buy" by Analysts2 hours agoBrightSpire Capital, Inc. (NYSE:BRSP) Receives Average Recommendation of "Hold" from AnalystsMarketBeatNYSE:BRSPRead BrightSpire Capital, Inc. (NYSE:BRSP) Receives Average Recommendation of "Hold" from Analysts2 hours agoCognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of "Moderate Buy" from AnalystsMarketBeatNASDAQ:CGTXRead Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of "Moderate Buy" from Analysts2 hours agoRadian Group Inc. (NYSE:RDN) Receives Average Rating of "Moderate Buy" from AnalystsMarketBeatNYSE:RDNRead Radian Group Inc. (NYSE:RDN) Receives Average Rating of "Moderate Buy" from Analysts2 hours agoNerdWallet, Inc. (NASDAQ:NRDS) Given Average Recommendation of "Hold" by BrokeragesMarketBeatNASDAQ:NRDSRead NerdWallet, Inc. (NASDAQ:NRDS) Given Average Recommendation of "Hold" by Brokerages2 hours agoEverQuote, Inc. (NASDAQ:EVER) Given Average Rating of "Moderate Buy" by BrokeragesMarketBeatNASDAQ:EVERRead EverQuote, Inc. (NASDAQ:EVER) Given Average Rating of "Moderate Buy" by Brokerages2 hours agoIndependent Bank Corp. (NASDAQ:INDB) Receives Average Rating of "Moderate Buy" from AnalystsMarketBeatNASDAQ:INDBRead Independent Bank Corp. (NASDAQ:INDB) Receives Average Rating of "Moderate Buy" from Analysts2 hours agoDaVita Inc. (NYSE:DVA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMarketBeatNYSE:DVARead DaVita Inc. (NYSE:DVA) Receives Consensus Recommendation of "Moderate Buy" from Analysts2 hours agoOptimum Communications, Inc. (NYSE:OPTU) Receives Average Rating of "Reduce" from BrokeragesMarketBeatNYSE:OPTURead Optimum Communications, Inc. (NYSE:OPTU) Receives Average Rating of "Reduce" from Brokerages2 hours agofuboTV Inc. (NYSE:FUBO) Given Average Rating of "Moderate Buy" by BrokeragesMarketBeatNYSE:FUBORead fuboTV Inc. (NYSE:FUBO) Given Average Rating of "Moderate Buy" by Brokerages2 hours agoSony Corporation (NYSE:SONY) Receives Consensus Rating of "Moderate Buy" from AnalystsMarketBeatNYSE:SONYRead Sony Corporation (NYSE:SONY) Receives Consensus Rating of "Moderate Buy" from Analysts2 hours agoIntegra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Recommendation of "Reduce" from AnalystsMarketBeatNASDAQ:IARTRead Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Recommendation of "Reduce" from Analysts2 hours agoCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from AnalystsMarketBeatNASDAQ:RNACRead Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from Analysts2 hours agoMyriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Reduce" from AnalystsMarketBeatNASDAQ:MYGNRead Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Reduce" from Analysts2 hours agoTelos Corporation (NASDAQ:TLS) Receives Average Recommendation of "Hold" from BrokeragesMarketBeatNASDAQ:TLSRead Telos Corporation (NASDAQ:TLS) Receives Average Recommendation of "Hold" from Brokerages2 hours agoOrganon & Co. (NYSE:OGN) Given Consensus Recommendation of "Reduce" by BrokeragesMarketBeatNYSE:OGNRead Organon & Co. (NYSE:OGN) Given Consensus Recommendation of "Reduce" by Brokerages2 hours agoCohu, Inc. (NASDAQ:COHU) Given Average Rating of "Moderate Buy" by BrokeragesMarketBeatNASDAQ:COHURead Cohu, Inc. (NASDAQ:COHU) Given Average Rating of "Moderate Buy" by Brokerages2 hours agoArtiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarketBeatNASDAQ:ARTVRead Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of "Moderate Buy" by Analysts Featured Articles and Offers3 Luxury Consumer Brands to Watch in a Beaten-Down SectorBy Nathan Reiff | September 16, 2026Iran War WARNING: Something Just ChangedFrom Banyan Hill Publishing (Ad)Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed EarningsBy Dan Schmidt | September 14, 2026Why Bitcoin ETFs May Be Worth Another Look as Inflows ReboundBy Nathan Reiff | September 13, 2026Running on Empty: 3 Energy Plays for Europe's Deep FreezeBy Jeffrey Neal Johnson | September 15, 2026$0. Later: $29.97.From Profits Run (Ad)3 Dividend Kings to Buy While They’re Still Beaten DownBy Thomas Hughes | September 14, 2026Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?By Ryan Hasson | September 12, 2026 Alert CategoriesAll AlertsAnalystCongressional TradesConsensusCorporate BuybackCorporate Event TranscriptStock ListDividendEarningsEarnings PreviewEarnings Transcript HighlightsEstimatesGuidanceInsider TradeLockup ExpirationMarketBeat List ArticlesOptionsPriceSEC FilingStock Split Page 1 of 267 1234567 Earlier › Earliest » Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
